- Home
- VYGR vs HLXC Comparison
VYGR vs HLXC Comparison
Compare VYGR & HLXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VYGR | HLXC |
|---|---|---|
| Founded | 2013 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 219.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYGR | HLXC |
|---|---|---|
| Price | $3.79 | $10.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 527.4K | 77.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $10.13 |
| 52 Week High | $5.55 | $10.35 |
Technical Indicators
Market Signals| Indicator | VYGR | HLXC |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | N/A |
| Support Level | $2.79 | N/A |
| Resistance Level | $3.73 | N/A |
| Average True Range (ATR) | 0.21 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 54.65 | 0.00 |
Price Performance
Historical ComparisonAbout VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About HLXC Helix Acquisition Corp. III Class A Ordinary Shares
Helix Acquisition Corp III is a blank check company.